Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

Arjun V. Balar, Matthew D. Galsky, Jonathan E. Rosenberg, Thomas Powles, Daniel P. Petrylak, Joaquim Bellmunt, Yohann Loriot, Andrea Necchi, Jean Hoffman-Censits, Jose Luis Perez-Gracia, Nancy A. Dawson, Michiel S. van der Heijden, Robert Dreicer, Sandy Srinivas, Margitta M. Retz, Richard W. Joseph, Alexandra Drakaki, Ulka N. Vaishampayan, Srikala S. Sridhar, David I. QuinnIgnacio Durán, David R. Shaffer, Bernhard J. Eigl, Petros D. Grivas, Evan Y. Yu, Shi Li, Edward E. Kadel, Zachary Boyd, Richard Bourgon, Priti S. Hegde, Sanjeev Mariathasan, Ann Christine Thåström, Oyewale O. Abidoye, Gregg D. Fine, Dean F. Bajorin

Research output: Contribution to journal › Article › peer-review

927 Scopus citations

Fingerprint

Dive into the research topics of 'Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences